This retrospective cohort study evaluated the effectiveness of a 23-valent pneumococcal polysaccharide vaccine in reducing hospital admission for pneumonia, otitis media and exacerbation of asthma or other syndromes due to Streptococcus pneumoniae in 9170 highrisk individuals. Cohort members were followed from 1 January 1998 to 31 December 2002. With regard to preventing hospitalization due to pneumonia, we observed a decrease in the incidence of 1/10 000 person-months and a reduction in the relative risk of 38% in the vaccinated cohort compared with the nonvaccinated subjects. A decrease in the risk of hospital admission for asthma, acute otitis media, chronic obstructive pulmonary disease and other respiratory infections was also observed in vaccinated compared with non-vaccinated subjects. The specificity of these findings was confirmed by the lack of a protective effect from vaccination for those outcomes, such as hospitalization 'for all causes' and 'other otorhinolaryngological diagnoses', that were not directly related to pneumococcal disease.
Introduction
Streptococcus pneumoniae is the main cause of pneumonia in the elderly and it is an important cause of infection of the middle ear, sinuses and trachea due to direct spread of the micro-organism from the nasopharyngeal site of colonization. S. pneumoniae also spreads via the blood circulatory system causing infection of the central nervous system, heart valves, bones and joints. 1 -3 The precise incidence of pneumococcal pneumonia is difficult to ascertain since routine diagnostic tests are not sufficiently sensitive, but at least 500 000 cases are estimated annually in the USA. 4, 5 Moreover, pneumococcal disease accounts for an estimated 3000 cases of meningitis, 50 000 cases of bacteraemia and 7 million cases of otitis media. 4 The main option for reducing the impact of infection in subjects aged over 2 years is immunoprophylaxis with a polysaccharide vaccine, a preventive measure that is recommended for those individuals with an increased likelihood of acquiring pneumococcal infection or who are at a severe risk of complications. 4,6 -8 Vaccination coverage is unsatisfactory in many countries and persistent uncertainties concerning the benefits may contribute to the under-use of the vaccine. Previous case-controlled studies and an indirect cohort study showed that the polysaccharide vaccine prevented 50 -70% of invasive pneumococcal disease. Prospective studies have provided inconclusive evidence that the vaccine reduces hospitalization for pneumonia, however. 9 -12 There is a lack of data on the effectiveness of the vaccine for reducing morbidity and hospitalization for otitis media, exacerbation of asthma or other syndromes in which S. pneumoniae infection is implicated.
We conducted a retrospective cohort study of around 10 000 frail and elderly adults to evaluate the effectiveness of a polysaccharide vaccine to prevent hospitalization for pneumonia, acute otitis media and other respiratory infections and syndromes.
Patients and methods

STUDY POPULATION
This cohort study was carried out in Genoa Province, which had a population of 870 553 inhabitants in January 2001. In January 2000, a large-scale programme of vaccination against S. pneumoniae was started. All individuals over 64 years of age, or those with an increased likelihood of acquiring pneumococcal infection, or those presenting with a serious risk of complications were invited to receive the pneumococcal vaccine. The following diseases or conditions were considered risk factors: asthma, chronic obstructive pulmonary disease (COPD), bronchitis, chronic respiratory disease, cardiovascular disease, chronic renal failure, diabetes mellitus, immunodeficiency and functional or anatomic asplenia. The invitation was proposed by officials from vaccination centres and nursing homes and by general practitioners, during an influenza vaccination campaign. Ethical approval and informed consent were not required for this study as vaccination was part of the routine care of patients at risk of pneumococcal infection and/or its complications.
The study population (Genoa cohort) consisted of subjects who were vaccinated with polysaccharide vaccine (Pneumo 23, Aventis Pasteur MSD, Lyon, France) between 1 January 2000 and 1 December 2002 at vaccination centres (Department of Prevention, ASL 3 'Genovese', Liguria Region, Italy) or at the nursing homes where they lived. Cohort members were followed from 1 January 1998 to 31 December 2002.
When the vaccination was given, each individual's name and identification code (personalized for each citizen) were recorded and the details were transferred to a database at the Department of Prevention (ASL 3 'Genovese', Liguria Region, Italy). ASL 3 'Genovese' maintains an administrative database with records of immunizations, diagnosis associated with hospitalization, presence of a co-morbidity, period and outcome of hospitalization and whether subjects lived in a nursing home. For analysis, vaccination data were matched with discharge diagnoses according to the International Classification of Disease (ICD-9-CM), 13 from all hospitals in the Genoa Province. Discharge data were obtained from the administrative database of Genoa Council. 491 F Ansaldi, V Turello, P Lai et al.
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The primary outcomes were the comparison of incidence, before and after vaccination, of hospitalization due to: all causes; asthma and asthmatic bronchitis (discharge code 493); COPD (490 -496); acute otitis media (382); pneumonia (480 -487); and other acute respiratory infections (acute nasopharyngitis, acute sinusitis, acute pharyngitis, acute tonsillitis, acute laryngitis and tracheitis, acute bronchitis and bronchiolitis, 460 -466).
A group of otorhinolaryngological diseases (described in this study as 'other ear nose and throat [ENT] diagnosis'), which included sialadenitis (527.2), nasal polyps (471), polyp of vocal cord or larynx (478.4), hearing loss (389), and tinnitus (388.3), was considered to be a non-specific outcome that was not related to S. pneumoniae disease and it was used to evaluate the specificity of the outcome evaluation.
The secondary outcome was the time spent in hospital for the above-mentioned diseases.
STATISTICAL ANALYSIS
Crude event rates were calculated by dividing the number of hospitalizations by the persontime for each outcome, and the results are presented as number of events, incidence before and after vaccination, and relative risk (RR) (before versus after vaccination) together with the 95% confidence interval (95% CI). The time required for hospitalization for each outcome, before and after vaccination, was compared using the Student's t-test. Logistic regression was performed in order to evaluate factors associated with at least one hospitalization, for each outcome, i.e. age, presence or absence of a co-morbidity, vaccination and living in a nursing home. In the logistic regression, to compare the risks of each outcome before and after vaccination, equal periods of time were considered for each subject.
The sample size allowed us to detect a non-null value of the difference in hospitalization for pneumonia of 2.5/10 000 person-months, using a power of 0.80, a significance level of 0.05 and an expected incidence of hospitalization with a discharge diagnosis code for pneumonia in unvaccinated and vaccinated individuals reported by Jackson et al. 9
Results
CHARACTERISTICS OF THE STUDY POPULATION
The Genoa cohort consisted of 9170 subjects who were observed for a period of 547 139 person-months, of which 392 036 (71.7%) were observed before and 155 103 (28.3%) were observed after pneumococcal vaccination. A total of 452 subjects died during the follow-up period after vaccination.
Demographic data and the prevalence of risk factors present at the time of vaccination are shown in Table 1 . The risk factors appeared to be related to age: more common in the 12 -64 year olds than in those over 64 years of age was the prevalence of asthma (12% versus 8%), COPD (30% versus 26.6%), immunodeficiency (1.9% versus 0.4%) and asplenia (0.6% versus 0.1%) while cardiovascular disease (13.3% versus 18.6%) and diabetes mellitus (4.9% versus 6.2%) were more common in the older groups. Bronchitis (16% versus 15.6%) and chronic renal failure (1.5% versus 1.2%) showed a similar prevalence in study groups containing subjects younger and older than 64 years.
A total of 8592 individuals (93.7% of the target population) received the influenza vaccine annually during the follow-up period. Influenza vaccine was administered at least three or four times during the 5-year followup period, to 8887 (96.9%) and 8785 (95.8%) subjects, respectively. All participants received at least two doses of influenza vaccine. 
CLINICAL OUTCOMES
The incidence of hospital admission for all causes, asthma or bronchitis, COPD, acute otitis media, pneumonia, other respiratory infections or other ENT diagnoses, as well as the time required for hospitalization for the above-mentioned diseases, are reported in Tables 2 and 3 , respectively. The estimated relative risk of hospitalization in nonvaccinated subjects was 82% (35 -145%) and 123% (36 -270%) higher than in vaccinated subjects for asthma or bronchitis and acute otitis media, respectively. A reduction in hospital admissions during the follow-up after vaccination was also observed for pneumonia, other respiratory infections and other ENT diagnoses, but the reductions were not statistically significant. The duration of hospitalization for asthma or bronchitis was significantly F Ansaldi, V Turello, P Lai et al. 
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longer during the pre-vaccination period than after vaccination (P = 0.039), while no statistically significant reduction was observed for other outcomes ( Table 3) .
The model of multivariate analysis included age, presence or absence of a comorbidity, pneumococcal vaccination and residence in a nursing home. The 'living in a nursing home' variable, from the initial model, was not retained due to its nonsignificant role in determining the dependent variables. Therefore, the final reduced model included age, presence or absence of a co-morbidity and vaccination (Table 4 ). In the multivariate analysis, lack of pneumococcal vaccination was associated F Ansaldi, V Turello, P Lai et al.
with a 64%, 23%, 125%, 38% and 87% increase in the risk of hospital admission for asthma or bronchitis, COPD, acute otitis media, pneumonia and other respiratory infections, respectively.
The role of immunization was not associated with hospitalization due to all causes or other ENT diagnoses. The presence of a co-morbidity was strongly associated with the risk of hospitalization for all outcomes, except acute otitis media. The 'age' variable was a significant factor in defining the risk of hospitalization: being 1 year older was associated with a significant increase in the risk of hospitalization for all causes and a decrease in the risk of hospitalization for asthma or bronchitis, acute otitis media, other respiratory infections and other ENT diagnoses (P < 0.05).
Discussion
This retrospective study, which included a large cohort of subjects who were over 64 years of age, had an increased likelihood of acquiring pneumococcal infection or who had a serious risk of complications, demonstrated an association between pneumococcal vaccination and a reduced risk of hospitalization for pneumonia and other non-invasive pneumococcal diseases.
With regard to the effectiveness of the vaccine to prevent hospitalization due to pneumonia, we observed a decrease in the incidence by 1/10 000 person-months and a reduction in the relative risk of 38% in the vaccinated cohort compared with the subjects before vaccination. The results of this retrospective study were not consistent with those of four meta-analyses of prospective randomized trials, which failed to demonstrate that the vaccination was associated with a reduction in the risk of this outcome measure. 14 -17 A recent retrospective study confirmed that pneumococcal vaccination did not reduce the risk of outpatient pneumonia and hospitalization for pneumonia. 9 Other recent studies, on the contrary, showed that pneumococcal vaccination had a protective effect in the elderly; the findings of a large-scale campaign with influenza and pneumococcal vaccines in elderly people strongly suggested a reduction in hospital admissions for influenza, pneumonia and invasive pneumococcal disease. However, it was difficult to estimate the relative importance of each of these two vaccines. 18 A retrospective cohort and a case-controlled study involving highrisk patients such as those with chronic lung disease as well as residents in a long-stay geriatric hospital, showed that vaccination resulted in a significant reduction in the risk of pneumonia, and hospitalization for pneumonia and influenza. 19, 20 There are a number of factors that might explain why the findings from previous studies have been different but it is difficult to estimate the relative importance of each factor. For example, immune response, probability of exposure and the attitude to hospitalization are all important factors in determining the effectiveness of the pneumococcal vaccine in reducing hospitalization. In the studies performed in less industrialized countries, the populations were relatively young and fit and would be expected to have a better immune response to the vaccine than those in industrialized countries where the vaccinees were elderly persons and those with serious underlying illness. Although 14% of our study population was aged less than 65 years, the pneumococcal vaccination was recommended for all participants according to the guidelines followed by a number of countries and there was no reason to suspect that our population had a better response than other cohorts in which this protective effect was F Ansaldi, V Turello, P Lai et al.
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not observed, such as the population studied by Jackson et al. 9 The 'age' variable was also found to be a significant factor in defining the risk of hospitalization in this study with every year's increase in age being associated with a significant increase in the risk of hospitalization for all causes and a decrease in the risk of hospitalization for asthma or bronchitis, acute otitis media, other respiratory infections and other ENT diagnoses. This finding could be related to the agedependent distribution of risk factors at the time of vaccination; indeed, asthma and COPD were more common in the younger age groups.
The incidence of pneumonia and the proportion of pneumococcal pneumonia cases play a fundamental role in estimating the effectiveness of the vaccine. Vaccine protection against pneumonia is very high in populations with high attack rates and where epidemics of one or two serotypes are common in overcrowded and poorly ventilated settings, such as young healthy Papua New Guinea highlanders or South African miners, or in high-risk patients such as nursing-home residents. 20 -22 Efficacy data from these populations cannot be extrapolated to frail subjects living in developed countries where the prevalence of pneumococcal carriage has fallen since the early part of the 20th century and the risk of pneumonia is lower. In populations in industrialized countries, the rate of hospitalization for pneumonia in non-vaccinated subjects aged over 65 years of age has been reported to range from 8.3 to 9.2/10 000 person-months, depending upon the case definition and the country. 9, 18, 23, 24 In the literature, S. pneumoniae accounts for about 20 -50% of the pneumonia cases requiring hospitalization, although if one focuses on the studies that used serological methods in addition to blood and sputum culture, this micro-organism was identified as the aetiological agent in > 50% of cases. 25 -28 The rate of hospitalization for pneumonia of 8.8 cases/ 10 000 person-months observed in the present study was in keeping with these observations. These similar rates of events support the validity of our methods and findings. The proportion of pneumonia cases requiring hospitalization due to pneumococcus remains generally unknown in Italy, although studies on a limited number of cases reported a percentage of 30 -50%. 29 Although our study population met the criteria for which pneumococcal vaccine is recommended in several countries, and the incidence of hospitalization for pneumonia in the Genoa cohort was in keeping with that observed in other developed countries, the effectiveness of the polysaccharide pneumococcal vaccine in the prevention of hospitalization for all causes of pneumonia clearly emerged from this cohort study. It is difficult to explain why our results are different to previous studies, but a number of factors should be taken into consideration when evaluating the effectiveness of vaccination in adults in developed countries. 30, 31 Nevertheless, our findings contribute to the debate about whether pneumococcal vaccine reduces the need for hospitalization for pneumonia. 30, 31 The effectiveness of the polysaccharide vaccine in preventing hospitalization for other conditions exacerbated or induced by non-invasive pneumococcal diseases such as asthma, bronchitis, COPD, acute otitis media and other respiratory infections in adults has not been investigated extensively. Recent reviews, mainly including trials on children, found very limited evidence of protection from the polysaccharide vaccine against asthma and acute otitis media. 32 -34 To our knowledge, this is the first report presenting evidence of a decrease in the F Ansaldi, V Turello, P Lai et al.
incidence of hospitalization for asthma, acute otitis media and other respiratory conditions and diseases in vaccinated compared with non-vaccinated adults.
Ours was a retrospective study and is, therefore, subject to the limitations of a nonrandomized study. The main issue was whether the vaccinated and non-vaccinated groups were similar with regard to risk distribution. In our study, the same subjects acted as the controls and were then subsequently vaccinated. Therefore, the vaccinated subjects were older and had a higher prevalence of risk factors. This clearly emerged from the analysis of the 'hospitalization for all causes' outcome; the incidence after vaccination increased by 21/10 000 person-months, and being 1 year older significantly increased the risk of hospitalization by 1%. Another confirmation of the specificity of these findings was that we did not observe a protective effect from vaccination in the multivariate analysis for those outcome measures, such as hospitalization 'for all causes' and 'other ENT diagnosis', that were not directly related to pneumococcal disease.
In conclusion, our study demonstrated that pneumococcal vaccination of frail and elderly subjects substantially improved the health of the study population, reducing hospital admissions for pneumonia, asthma and bronchitis, COPD, acute otitis media and other respiratory infections.
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